These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23203566)

  • 21. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
    Fernández-Nebro A; Tomero E; Ortiz-Santamaría V; Castro MC; Olivé A; de Haro M; Portales RG; González-Mari MV; Laffón A; García-Vicuña R
    Am J Med; 2005 May; 118(5):552-6. PubMed ID: 15866260
    [No Abstract]   [Full Text] [Related]  

  • 22. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I
    Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278
    [No Abstract]   [Full Text] [Related]  

  • 25. Atypical cutaneous tuberculosis in a patient with rheumatoid arthritis treated with infliximab.
    Asano Y; Kano Y; Shiohara T
    Acta Derm Venereol; 2008; 88(2):183-4. PubMed ID: 18311458
    [No Abstract]   [Full Text] [Related]  

  • 26. [Infliximab for therapy of rheumatoid arthritis].
    Amano K
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():517-20. PubMed ID: 15799410
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 28. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.
    Richette P; Dieudé P; Damiano J; Lioté F; Orcel P; Bardin T
    J Rheumatol; 2004 Oct; 31(10):2079-81. PubMed ID: 15468380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pericardial effusions on anti-TNF therapy for rheumatoid arthritis--a drug side effect or uncontrolled systemic disease?
    Edwards MH; Leak AM
    Rheumatology (Oxford); 2009 Mar; 48(3):316-7. PubMed ID: 19106166
    [No Abstract]   [Full Text] [Related]  

  • 30. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua C; Gonzalez-Gay MA; Quevedo V
    J Rheumatol; 2006 Feb; 33(2):433; author reply 433-4. PubMed ID: 16465676
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.
    Riolo G; Towheed TE
    J Rheumatol; 2012 Jan; 39(1):192-4. PubMed ID: 22210682
    [No Abstract]   [Full Text] [Related]  

  • 33. [Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():444-7. PubMed ID: 15799396
    [No Abstract]   [Full Text] [Related]  

  • 34. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung.
    Weinblatt ME; Abbott GF; Koreishi AF
    N Engl J Med; 2009 Apr; 360(17):1770-9. PubMed ID: 19387019
    [No Abstract]   [Full Text] [Related]  

  • 35. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy.
    Berthelot CN; George SJ; Hsu S
    J Am Acad Dermatol; 2005 Nov; 53(5 Suppl 1):S260-2. PubMed ID: 16227104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker.
    Agarwal PK; Gallaghar M; Murphy E; Virdi M
    Indian J Ophthalmol; 2007; 55(3):230-2. PubMed ID: 17456948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab-associated third nerve palsy.
    Farukhi FI; Bollinger K; Ruggieri P; Lee MS
    Arch Ophthalmol; 2006 Jul; 124(7):1055-7. PubMed ID: 16832034
    [No Abstract]   [Full Text] [Related]  

  • 38. CNS demyelination during anti-tumor necrosis factor alpha therapy.
    Bellesi M; Logullo F; Di Bella P; Provinciali L
    J Neurol; 2006 May; 253(5):668-9. PubMed ID: 16311894
    [No Abstract]   [Full Text] [Related]  

  • 39. Comments on Falgarone et al. editorial entitled "TNFalpha antagonists in rheumatoid arthritis patients seen in everyday practice".
    Legoff P
    Joint Bone Spine; 2008 Oct; 75(5):626; author reply 626. PubMed ID: 18805723
    [No Abstract]   [Full Text] [Related]  

  • 40. Peripheral neuropathy during infliximab therapy for rheumatoid arthritis.
    El Aidli S; Gaïes E; Cherif F; Zaiem A; Daghfous R; Lakhal M
    Presse Med; 2014 Sep; 43(9):1012-4. PubMed ID: 24742611
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.